A Research Study for Patients With Metastatic Renal Cell Carcinoma
The purpose of this study is to evaluate the activity of FK228 in metastatic renal cell carcinoma (RCC) patients who have developed progressive disease (PD) following or during treatment with immunotherapy.
Carcinoma, Renal Cell|Neoplasm Metastasis
DRUG: FK228 (romidepsin)
To evaluate the rate of objective response (the best response of Complete Response (CR), Partial Response (PR))., Up to 6 months
Rate of disease control, Complete Response, Partial Response, or Stable Disease, Up to 6 months|Time to objective disease progression., Up to 6 months|Number of Participants with Adverse Events, Up to 6 months|Change from screening assessment to the final study visit in Karnofsky performance status., Up to 6 months|Steady state plasma concentrations, Up to 6 months
The purpose of this study is to evaluate the activity of FK228 in metastatic renal cell carcinoma (RCC) patients who have developed progressive disease (PD) following or during treatment with immunotherapy.